UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Tests of the liver's capacity to transport organic anions and metabolize drugs

Author
Lawrence S Friedman, MD
Section Editor
Sanjiv Chopra, MD, MACP
Deputy Editor
Anne C Travis, MD, MSc, FACG, AGAF

INTRODUCTION

A number of blood tests are available that reflect the condition of the liver. The most common tests used in clinical practice include the serum aminotransferases, bilirubin, alkaline phosphatase, albumin, and prothrombin time. These tests are often referred to as "liver function tests," although this term is somewhat misleading since most do not accurately reflect how well the liver is functioning, and abnormal values can be caused by diseases unrelated to the liver. In addition, these tests may be normal in patients who have advanced liver disease.

Several specialized tests have also been developed (such as indocyanine green clearance), which, although uncommonly used in clinical practice, can measure specific aspects of hepatic function.

Despite their limitations, liver biochemical and function tests have many applications in clinical medicine:

They provide a noninvasive method to screen for the presence of liver disease. The serum aminotransferases, for example, used to be part of panel of tests used to screen all blood donors in the United States for the presence of transmissible viruses before specific viral tests became available.

They can be used to measure the efficacy of treatments for liver disease (such as immunosuppressant agents for autoimmune hepatitis). (See "Autoimmune hepatitis: Treatment".)

                 

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Thu Aug 11 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Rosenthal SM, White EC. Studies in the value of selected phthalein compounds in the estimation of hepatic function. J Pharmacol Exp Ther 1924; 24:265.
  2. Baker KJ. Binding of sulfobromophthalein (BSP) sodium and indocyanine green (ICG) by plasma alpha-1 lipoproteins. Proc Soc Exp Biol Med 1966; 122:957.
  3. WHEELER HO, MELTZER JI, BRADLEY SE. Biliary transport and hepatic storage of sulfobromophthalein sodium in the unanesthetized dog, in normal man, and in patients with hepatic disease. J Clin Invest 1960; 39:1131.
  4. Häcki W, Bircher J, Preisig R. A new look at the plasma disappearance of sulfobromophthalein (BSP): correlation with the BSP transport maximum and the hepatic plasma flow in man. J Lab Clin Med 1976; 88:1019.
  5. IBER FL. REACTIONS TO SULFOBROMOPHTHALEIN SODIUM INJECTION, USP2. Bull Johns Hopkins Hosp 1965; 116:132.
  6. LEEVY CM, BENDER J. PHYSIOLOGY OF DYE EXTRACTION BY THE LIVER: COMPARATIVE STUDIES OF SULFOBROMOPHTHALEIN AND INDOCYANINE GREEN. Ann N Y Acad Sci 1963; 111:161.
  7. CHERRICK GR, STEIN SW, LEEVY CM, DAVIDSON CS. Indocyanine green: observations on its physical properties, plasma decay, and hepatic extraction. J Clin Invest 1960; 39:592.
  8. Dejeux JF, et al. Hepatic clearance and biliary excretion of unconjugated dyes in the Dubin-Johnson syndrome. Gut 1971; 12:758.
  9. Kanda M, Taniguchi K, Awazu K. Continuous monitoring of cardiogreen removal by a diseased liver using an optical sensor. Proc SPIE 1988; 904:39.
  10. De Gasperi A, Mazza E, Prosperi M. Indocyanine green kinetics to assess liver function: Ready for a clinical dynamic assessment in major liver surgery? World J Hepatol 2016; 8:355.
  11. Paumgartner G. The handling of indocyanine green by the liver. Schweiz Med Wochenschr 1975; 105:1.
  12. Bircher J. Quantitative assessment of deranged hepatic function: a missed opportunity? Semin Liver Dis 1983; 3:275.
  13. Wynne HA, Goudevenos J, Rawlins MD, et al. Hepatic drug clearance: the effect of age using indocyanine green as a model compound. Br J Clin Pharmacol 1990; 30:634.
  14. Skak C, Keiding S. Methodological problems in the use of indocyanine green to estimate hepatic blood flow and ICG clearance in man. Liver 1987; 7:155.
  15. Parker BM, Cywinski JB, Alster JM, et al. Predicting immunosuppressant dosing in the early postoperative period with noninvasive indocyanine green elimination following orthotopic liver transplantation. Liver Transpl 2008; 14:46.
  16. Zipprich A, Kuss O, Rogowski S, et al. Incorporating indocyanin green clearance into the Model for End Stage Liver Disease (MELD-ICG) improves prognostic accuracy in intermediate to advanced cirrhosis. Gut 2010; 59:963.
  17. Olmedilla L, Lisbona CJ, Pérez-Peña JM, et al. Early Measurement of Indocyanine Green Clearance Accurately Predicts Short-Term Outcomes After Liver Transplantation. Transplantation 2016; 100:613.
  18. Ahlberg J, Angelin B, Björkhem I, Einarsson K. Individual bile acids in portal venous and systemic blood serum of fasting man. Gastroenterology 1977; 73:1377.
  19. Berry W, Reichen J. Bile acid metabolism: its relation to clinical disease. Semin Liver Dis 1983; 3:330.
  20. LaRusso NF, Korman MG, Hoffman NE, Hofmann AF. Dynamics of the enterohepatic circulation of bile acids. Postprandial serum concentrations of conjugates of cholic acid in health, cholecystectomized patients, and patients with bile acid malabsorption. N Engl J Med 1974; 291:689.
  21. LaRusso NF, Hoffman NE, Korman MG, et al. Determinants of fasting and postprandial serum bile acid levels in healthy man. Am J Dig Dis 1978; 23:385.
  22. Mouzaki M, Wang AY, Bandsma R, et al. Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease. PLoS One 2016; 11:e0151829.
  23. Barnes S, Spenney JG. Improved enzymatic assays for bile acids using resazurin and NADH oxidoreductase from Clostridium kluyveri. Clin Chim Acta 1980; 102:241.
  24. Roda A, Kricka LJ, DeLuca M, Hofmann AF. Bioluminescence measurement of primary bile acids using immobilized 7 alpha-hydroxysteroid dehydrogenase: application to serum bile acids. J Lipid Res 1982; 23:1354.
  25. Pennington CR, Ross PE, Bouchier IA. Serum bile acids in the diagnosis of hepatobiliary disease. Gut 1977; 18:903.
  26. Demers LM, Hepner G. Radioimmunoassay of bile acids in serum. Clin Chem 1976; 22:602.
  27. Schalm SW, van Berge-Henegouwen GP, Hofmann AF, et al. Radioimmunoassay of bile acids: development, validation, and preliminary application of an assay for conjugates of chenodeoxycholic acid. Gastroenterology 1977; 73:285.
  28. Angelin B, Bjökhem I, Einarsson K. Individual serum bile acid concentrations in normo- and hyperlipoproteinemia as determined by mass fragmentography: relation to bile acid pool size. J Lipid Res 1978; 19:527.
  29. Lunzer M, Barnes P, Byth K, O'Halloran M. Serum bile acid concentrations during pregnancy and their relationship to obstetric cholestasis. Gastroenterology 1986; 91:825.
  30. Brites D, Rodrigues CM, Oliveira N, et al. Correction of maternal serum bile acid profile during ursodeoxycholic acid therapy in cholestasis of pregnancy. J Hepatol 1998; 28:91.
  31. Batta AK, Arora R, Salen G, et al. Characterization of serum and urinary bile acids in patients with primary biliary cirrhosis by gas-liquid chromatography-mass spectrometry: effect of ursodeoxycholic acid treatment. J Lipid Res 1989; 30:1953.
  32. Poupon RE, Chrétien Y, Poupon R, Paumgartner G. Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy. Hepatology 1993; 17:599.
  33. Milstein HJ, Bloomer JR, Klatskin G. Serum bile acids in alcoholic liver disease. Comparison with histological features of the disease. Am J Dig Dis 1976; 21:281.
  34. Skrede S, Solberg HE, Blomhoff JP, Gjone E. Bile acids measured in serum during fasting as a test for liver disease. Clin Chem 1978; 24:1095.
  35. Mishler JM 4th, Barbosa L, Mihalko LJ, McCarter H. Serum bile acids and alanine aminotransferase concentrations. Comparison of efficacy as indirect means of identifying carriers of non-A, non-B hepatitis agents and of onset, severity, and duration of posttransfusion non-A, non-B hepatitis in recipients. JAMA 1981; 246:2340.
  36. Ferraris R, Colombatti G, Fiorentini MT, et al. Diagnostic value of serum bile acids and routine liver function tests in hepatobiliary diseases. Sensitivity, specificity, and predictive value. Dig Dis Sci 1983; 28:129.
  37. Rickers H, Christensen M, Arnfred T, et al. The diagnostic value of fasting serum total bile acid concentration in patients with suspected liver disease. A prospective, consecutive study. Scand J Gastroenterol 1982; 17:565.
  38. Roda A, Roda E, Sama C, et al. Serum primary bile acids in Gilbert's syndrome. Gastroenterology 1982; 82:77.
  39. Briheim G, Frydén A, Tobiasson P. Serum bile acids in Gilbert's syndrome before and after reduced caloric intake. Scand J Gastroenterol 1982; 17:877.
  40. Alpert S, Mosher M, Shanske A, Arias IM. Multiplicity of hepatic excretory mechanisms for organic anions. J Gen Physiol 1969; 53:238.
  41. Festi D, Morselli Labate AM, Roda A, et al. Diagnostic effectiveness of serum bile acids in liver diseases as evaluated by multivariate statistical methods. Hepatology 1983; 3:707.
  42. Monroe PS, Baker AL, Schneider JF, et al. The aminopyrine breath test and serum bile acids reflect histologic severity in chronic hepatitis. Hepatology 1982; 2:317.
  43. Einarsson K, Angelin B, Björkhem I, Glaumann H. The diagnostic value of fasting individual serum bile acids in anicteric alcoholic liver disease: relation to liver morphology. Hepatology 1985; 5:108.
  44. Jones MB, Weinstock S, Koretz RL, et al. Clinical value of serum bile acid levels in chronic hepatitis. Dig Dis Sci 1981; 26:978.
  45. Hepner GW, Vesell ES. Assessment of aminopyrine metabolism in man by breath analysis after oral administration of 14C-aminopyrine. Effects of phenobarbital, disulfiram and portal cirrhosis. N Engl J Med 1974; 291:1384.
  46. Shreeve WW, Shoop JD, Ott DG, McInteer BB. Test for alcoholic cirrhosis by conversion of [14C]- or [13C]galactose to expired CO2. Gastroenterology 1976; 71:98.
  47. Breen KJ, et al. 14C-phenacetin breath test in the assessment of hepatic function. Gastroenterology 1977; 72:1033.
  48. Hepner GW, Vesell ES, Lipton A, et al. Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant drug therapy: diazepam breath test and correlations in drug elimination. J Lab Clin Med 1977; 90:440.
  49. Pijls KE, de Vries H, Nikkessen S, et al. Critical appraisal of 13C breath tests for microsomal liver function: aminopyrine revisited. Liver Int 2014; 34:487.
  50. Lauterburg BH, Bircher J. Expiratory measurement of maximal amino-pyrine demethylation in vivo: effect of phenobarbital, partial hepatectomy, protacaval shunt and bile duct ligation in the rat. J Pharmacol Exp Ther 1976; 196:501.
  51. Hepner GW, Vesell ES. Quantitative assessment of hepatic function by breath analysis after oral administration of (14C)aminopyrine. Ann Intern Med 1975; 83:632.
  52. Carlisle R, Galambos JT, Warren WD. The relationship between conventional liver tests, quantitative function tests, and histopathology in cirrhosis. Dig Dis Sci 1979; 24:358.
  53. Bircher J, Küpfer A, Gikalov I, Preisig R. Aminopyrine demethylation measured by breath analysis in cirrhosis. Clin Pharmacol Ther 1976; 20:484.
  54. Giannini EG, Fasoli A, Borro P, et al. 13C-galactose breath test and 13C-aminopyrine breath test for the study of liver function in chronic liver disease. Clin Gastroenterol Hepatol 2005; 3:279.
  55. Giannini E, Fasoli A, Chiarbonello B, et al. 13C-aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther 2002; 16:717.
  56. Hepner GW, Vesell ES. Aminopyrine disposition: studies on breath, saliva, and urine of normal subjects and patients with liver disease. Clin Pharmacol Ther 1976; 20:654.
  57. Baker AL, Kotake AN, Schoeller DA. Clinical utility of breath tests for the assessment of hepatic function. Semin Liver Dis 1983; 3:318.
  58. Galizzi J, Long RG, Billing BH, Sherlock S. Assessment of the (14C) aminopyrine breath test in liver disease. Gut 1978; 19:40.
  59. Schütte K, Seidensticker R, Milbradt O, et al. Assessment and monitoring of liver function by ¹³C-aminopyrine breath test after selective transarterial chemoembolisation of hepatocellular carcinoma. Z Gastroenterol 2015; 53:21.
  60. Hofman A. The aminopyrine demethylation breath test and the serum bile acid level: Nominated but not yet elected to join the common liver tests. Hepatology 1982; 4:512.
  61. Monroe P, Baker AL, Glagov S, Sitrin M. Management of liver failure in a patient following jejunoileal bypass. Gastroenterology 1980; 78:1593.
  62. Schneider JF, Baker AL, Haines NW, et al. Aminopyrine N-demethylation: a prognostic test of liver function in patients with alcoholic liver disease. Gastroenterology 1980; 79:1145.
  63. Rocco A, de Nucci G, Valente G, et al. 13C-aminopyrine breath test accurately predicts long-term outcome of chronic hepatitis C. J Hepatol 2012; 56:782.
  64. Gill RA, Goodman MW, Golfus GR, et al. Aminopyrine breath test predicts surgical risk for patients with liver disease. Ann Surg 1983; 198:701.
  65. Henry DA, Kitchingman G, Langman MJ. [14C]Aminopyrine breath analysis and conventional biochemical tests as predictors of survival in cirrhosis. Dig Dis Sci 1985; 30:813.
  66. Tygstrup N. Determination of the hepatic elimination capacity (Lm) of galactose by a single injection. Scand J Lab Clin Invest 1966; 18(Suppl 92):118.
  67. Tengström B. The discriminatory ability of a galactose tolerance test and some other tests in the diagnosis of cirrhosis of the liver, hepatitis and biliary obstruction. Scand J Clin Lab Invest 1969; 23:159.
  68. Schmidt LE, Ott P, Tygstrup N. Galactose elimination capacity as a prognostic marker in patients with severe acetaminophen-induced hepatotoxicity: 10 years' experience. Clin Gastroenterol Hepatol 2004; 2:418.
  69. TYGSTRUP N. THE GALACTOSE ELIMINATION CAPACITY IN RELATION TO CLINICAL AND LABORATORY FINDINGS IN PATIENTS WITH CIRRHOSIS. Acta Med Scand 1964; 175:291.
  70. Christensen E, Bremmelgaard A, Bahnsen M, et al. Prediction of fatality in fulminant hepatic failure. Scand J Gastroenterol 1984; 19:90.
  71. Gluud C, Henriksen JH, Nielsen G. Prognostic indicators in alcoholic cirrhotic men. Hepatology 1988; 8:222.
  72. Albers I, Hartmann H, Bircher J, Creutzfeldt W. Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. Scand J Gastroenterol 1989; 24:269.
  73. Renner E, Wietholtz H, Huguenin P, et al. Caffeine: a model compound for measuring liver function. Hepatology 1984; 4:38.
  74. Joeres R, Klinker H, Heusler H, et al. Influence of smoking on caffeine elimination in healthy volunteers and in patients with alcoholic liver cirrhosis. Hepatology 1988; 8:575.
  75. Jost G, Wahlländer A, von Mandach U, Preisig R. Overnight salivary caffeine clearance: a liver function test suitable for routine use. Hepatology 1987; 7:338.
  76. Mizuno A, Uematsu T, Gotoh S, et al. The measurement of caffeine concentration in scalp hair as an indicator of liver function. J Pharm Pharmacol 1996; 48:660.
  77. Park GJ, Katelaris PH, Jones DB, et al. Validity of the 13C-caffeine breath test as a noninvasive, quantitative test of liver function. Hepatology 2003; 38:1227.
  78. Konstantinou D, Margariti E, Hadziyannis E, et al. Significance of the (13)C-caffeine breath test for patients with cirrhosis. Ann Gastroenterol 2014; 27:53.
  79. Oellerich M, Raude E, Burdelski M, et al. Monoethylglycinexylidide formation kinetics: a novel approach to assessment of liver function. J Clin Chem Clin Biochem 1987; 25:845.
  80. Huang YS, Lee SD, Deng JF, et al. Measuring lidocaine metabolite--monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis. J Hepatol 1993; 19:140.
  81. Shiffman ML, Luketic VA, Sanyal AJ, et al. Hepatic lidocaine metabolism and liver histology in patients with chronic hepatitis and cirrhosis. Hepatology 1994; 19:933.
  82. Oellerich M, Burdelski M, Ringe B, et al. Lignocaine metabolite formation as a measure of pre-transplant liver function. Lancet 1989; 1:640.
  83. Oellerich M, Burdelski M, Ringe B, et al. Functional state of the donor liver and early outcome of transplantation. Transplant Proc 1991; 23:1575.
  84. Zotz RB, von Schönfeld J, Erhard J, et al. Value of an extended monoethylglycinexylidide formation test and other dynamic liver function tests in liver transplant donors. Transplantation 1997; 63:538.